Current and Novel Inhibitors of HIV Protease
Author Information
Author(s): Pokorná Jana, Machala Ladislav, Řezáčová Pavlína, Konvalinka Jan
Primary Institution: Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic
Conclusion
The review discusses the development and clinical success of HIV protease inhibitors, highlighting the need for novel compounds to combat drug resistance and improve patient outcomes.
Supporting Evidence
- The introduction of HIV protease inhibitors in 1995 significantly decreased mortality among HIV-positive patients.
- Nine protease inhibitors are currently FDA-approved and are used in clinical practice.
- Resistance development is a major challenge due to the high mutation rate of HIV.
Takeaway
HIV protease inhibitors help stop the virus from spreading, but new and better drugs are needed because some viruses can become resistant to them.
Methodology
The review summarizes the pharmacokinetic properties, side effects, and resistance profiles of currently available HIV protease inhibitors and discusses compounds in clinical development.
Limitations
The review does not provide new experimental data but summarizes existing literature.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website